Free Trial

Mizuho's Rating of BridgeBio Pharma on 9/1/2026

On September 1, 2026, Mizuho updated its outlook on BridgeBio Pharma (NASDAQ:BBIO) with the action "Boost Price Target", setting a price target of $110.00. MarketBeat All Access subscribers can view the full ratings details, 12-month ROI, historical price target changes, and related news coverage on this page.

unlock icon  Upgrade to MarketBeat All Access

This premium research tool is available to MarketBeat All Access subscribers only. Log in to your account or sign up below.

Already have an account? Log in here.

More Ratings from Mizuho

DateCompanyAction
10/15/2026
FMC Corporation stock logo
FMC
FMC
Set Price Target
10/15/2026
EOG Resources, Inc. stock logo
EOG
EOG Resources
Set Price Target
10/15/2026
APA Corporation stock logo
APA
APA
Boost Price Target
10/15/2026
ServiceNow, Inc. stock logo
NOW
ServiceNow
Set Price Target
10/15/2026
Rapid7, Inc. stock logo
RPD
Rapid7
Boost Price Target
10/15/2026
Palantir Technologies Inc. stock logo
PLTR
Palantir Technologies
Boost Price Target
More Ratings From Mizuho